{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:47:36Z","timestamp":1789728456547,"version":"4.0.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The debate about surgical resection of primary tumor (PT) in <jats:italic>de novo<\/jats:italic> metastatic breast cancer (MBC) patients persists. We explored this approach\u2019s outcomes in patients included in a retrospective registry, named <jats:italic>El \u00c1lamo<\/jats:italic>, of breast cancer patients diagnosed in Spain (1990\u20132001). In this analysis we only included <jats:italic>de novo<\/jats:italic> MBC patients, 1415 of whom met the study\u2019s criteria. Descriptive, Kaplan-Meier and Cox regression analyses were carried out. Median age was 63.1 years, 49.2% of patients had single-organ metastasis (skin\/soft tissue [16.3%], bone [33.8%], or viscera [48.3%]). PT surgery (S) was performed in 44.5% of the cases. S-group patients were younger, had smaller tumors, higher prevalence of bone and oligometastatic disease, and lower prevalence of visceral involvement. With a median follow-up of 23.3 months, overall survival (OS) was 39.6 versus 22.4 months (HR\u2009=\u20090.59, p\u2009&lt;\u20090.0001) in the S- and non-S groups, respectively. The S-group OS benefit remained statistically and clinically significant regardless of metastatic location, histological type, histological grade, hormone receptor status and tumor size. PT surgery (versus no surgery) was associated with an OS benefit suggesting that loco-regional PT control may be considered in selected MBC patients. Data from randomized controlled trials are of utmost importance to confirm these results.<\/jats:p>","DOI":"10.1038\/s41598-019-55765-9","type":"journal-article","created":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T11:02:42Z","timestamp":1577444562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM\/El Alamo Registry)"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2606-9538","authenticated-orcid":false,"given":"Sara","family":"Lopez-Tarruella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Escudero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Pollan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9237-3231","authenticated-orcid":false,"given":"Miguel","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Jara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Guerrero-Zotano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Garc\u00eda-Saenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Santaballa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purificaci\u00f3n","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3897-2262","authenticated-orcid":false,"given":"Antonio","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norberto","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Llombart-Cussac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainhara","family":"Lahuerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"de la Haba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"L\u00f3pez-Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,27]]},"reference":[{"key":"55765_CR1","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1056\/NEJM199111073251909","volume":"325","author":"L Norton","year":"1991","unstructured":"Norton, L. Metastatic breast cancer. Length and quality of life. N. Engl. J. Med. 325, 1370\u20131371 (1991).","journal-title":"N. Engl. J. Med."},{"key":"55765_CR2","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1053\/j.seminoncol.2005.07.030","volume":"33","author":"I Smith","year":"2006","unstructured":"Smith, I. Goals of treatment for patients with metastatic breast cancer. Semin. Oncol. 33, S2\u20135 (2006).","journal-title":"Semin. Oncol."},{"key":"55765_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/annonc\/mdf101","volume":"13","author":"F Cardoso","year":"2002","unstructured":"Cardoso, F. et al. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann. Oncol. 13, 197\u2013207 (2002).","journal-title":"Ann. Oncol."},{"issue":"Suppl 3","key":"55765_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1634\/theoncologist.10-90003-20","volume":"10","author":"J O\u2019Shaughnessy","year":"2005","unstructured":"O\u2019Shaughnessy, J. Extending survival with chemotherapy in metastatic breast cancer. The Oncologist 10(Suppl 3), 20\u201329 (2005).","journal-title":"The Oncologist"},{"key":"55765_CR5","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00432-016-2306-1","volume":"143","author":"D H\u00f6lzel","year":"2017","unstructured":"H\u00f6lzel, D. et al. Survival of de novo stage IV breast cancer patients over three decades. Journal of Cancer Research and Clinical Oncology 143, 509\u2013519 (2017).","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"55765_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/cncr.11859","volume":"100","author":"SH Giordano","year":"2004","unstructured":"Giordano, S. H. et al. Is breast cancer survival improving? Cancer 100, 44\u201352 (2004).","journal-title":"Cancer"},{"key":"55765_CR7","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/cncr.21359","volume":"104","author":"A Gennari","year":"2005","unstructured":"Gennari, A., Conte, P., Rosso, R., Orlandini, C. & Bruzzi, P. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 104, 1742\u20131750 (2005).","journal-title":"Cancer"},{"key":"55765_CR8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.breast.2016.10.005","volume":"31","author":"M Sundquist","year":"2017","unstructured":"Sundquist, M., Brudin, L. & Tejler, G. Improved survival in metastatic breast cancer 1985\u20132016. Breast 31, 46\u201350 (2017).","journal-title":"Breast"},{"key":"55765_CR9","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00259-007-0580-5","volume":"35","author":"TF Cermik","year":"2008","unstructured":"Cermik, T. F., Mavi, A., Basu, S. & Alavi, A. Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer. Eur. J. Nucl. Med. Mol. Imaging 35, 475\u2013483 (2008).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"55765_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2967\/jnumed.112.106864","volume":"54","author":"D Groheux","year":"2013","unstructured":"Groheux, D. et al. 18F-FDG PET\/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging. J Nucl Med 54, 5\u201311 (2013).","journal-title":"J Nucl Med"},{"key":"55765_CR11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s10549-016-3845-5","volume":"157","author":"A Di Meglio","year":"2016","unstructured":"Di Meglio, A. et al. Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. Breast Cancer Res Treat 157, 587\u2013596 (2016).","journal-title":"Breast Cancer Res Treat"},{"key":"55765_CR12","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.breast.2007.01.001","volume":"16","author":"MF Ernst","year":"2007","unstructured":"Ernst, M. F. et al. Trends in the prognosis of patients with primary metastatic breast cancer diagnosed between 1975 and 2002. Breast (Edinburgh, Scotland) 16, 344\u2013351 (2007).","journal-title":"Breast (Edinburgh, Scotland)"},{"key":"55765_CR13","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1002\/cncr.27819","volume":"119","author":"AJ Tevaarwerk","year":"2013","unstructured":"Tevaarwerk, A. J. et al. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer 119, 1140\u20131148 (2013).","journal-title":"Cancer"},{"key":"55765_CR14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1001\/jamasurg.2015.4539","volume":"151","author":"A Thomas","year":"2016","unstructured":"Thomas, A., Khan, S. A., Chrischilles, E. A. & Schroeder, M. C. Initial Surgery and Survival in Stage IV Breast Cancer in the United States, 1988\u20132011. JAMA Surg 151, 424\u2013431 (2016).","journal-title":"JAMA Surg"},{"key":"55765_CR15","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1093\/jnci\/djq029","volume":"102","author":"O Pagani","year":"2010","unstructured":"Pagani, O. et al. International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured? JNCI Journal of the National Cancer Institute 102, 456\u2013463 (2010).","journal-title":"JNCI Journal of the National Cancer Institute"},{"key":"55765_CR16","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1200\/JCO.2008.16.1026","volume":"26","author":"E Andreopoulou","year":"2008","unstructured":"Andreopoulou, E. & Hortobagyi, G. N. Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy. J. Clin. Oncol. 26, 3660\u20133662 (2008).","journal-title":"J. Clin. Oncol."},{"key":"55765_CR17","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1200\/JCO.2002.20.3.620","volume":"20","author":"GN Hortobagyi","year":"2002","unstructured":"Hortobagyi, G. N. Can we cure limited metastatic breast cancer? J. Clin. Oncol. 20, 620\u2013623 (2002).","journal-title":"J. Clin. Oncol."},{"key":"55765_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.breast.2004.10.003","volume":"14","author":"CR Tait","year":"2005","unstructured":"Tait, C. R., Waterworth, A., Loncaster, J., Horgan, K. & Dodwell, D. The oligometastatic state in breast cancer: hypothesis or reality. Breast (Edinburgh, Scotland) 14, 87\u201393 (2005).","journal-title":"Breast (Edinburgh, Scotland)"},{"key":"55765_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000358750","volume":"9","author":"S Di Lascio","year":"2014","unstructured":"Di Lascio, S. & Pagani, O. Oligometastatic breast cancer: a shift from palliative to potentially curative treatment? Breast Care (Basel) 9, 7\u201314 (2014).","journal-title":"Breast Care (Basel)"},{"key":"55765_CR20","doi-asserted-by":"crossref","unstructured":"Salama, J. K. & Chmura, S. J. Surgery or ablative radiotherapy for breast cancer oligometastases. Am Soc Clin Oncol Educ Book, e8\u201315 (2015).","DOI":"10.14694\/EdBook_AM.2015.35.e8"},{"key":"55765_CR21","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S1470-2045(12)70510-7","volume":"14","author":"AC Tree","year":"2013","unstructured":"Tree, A. C. et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol 14, e28\u201337 (2013).","journal-title":"Lancet Oncol"},{"key":"55765_CR22","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1007\/s12032-012-0310-0","volume":"29","author":"F Petrelli","year":"2012","unstructured":"Petrelli, F. & Barni, S. Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regression. Med Oncol 29, 3282\u20133290 (2012).","journal-title":"Med Oncol"},{"key":"55765_CR23","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3892\/mco.2016.778","volume":"4","author":"H Headon","year":"2016","unstructured":"Headon, H., Wazir, U., Kasem, A. & Mokbel, K. Surgical treatment of the primary tumour improves the overall survival in patients with metastatic breast cancer: A systematic review and meta-analysis. Mol Clin Oncol 4, 863\u2013867 (2016).","journal-title":"Mol Clin Oncol"},{"key":"55765_CR24","first-page":"820","volume":"12","author":"T Lee","year":"2014","unstructured":"Lee, T. & Isaacs, C. Treatment of primary breast tumors in de novo metastatic breast cancer. Clin Adv Hematol Oncol 12, 820\u2013827 (2014).","journal-title":"Clin Adv Hematol Oncol"},{"key":"55765_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.radonc.2010.02.028","volume":"96","author":"C Bourgier","year":"2010","unstructured":"Bourgier, C. et al. Breast radiotherapy as part of loco-regional treatments in stage IV breast cancer patients with oligometastatic disease. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology 96, 199\u2013203 (2010).","journal-title":"Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology"},{"key":"55765_CR26","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1200\/JCO.2008.19.5396","volume":"27","author":"R Le Scodan","year":"2009","unstructured":"Le Scodan, R. et al. Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy. J. Clin. Oncol. 27, 1375\u20131381 (2009).","journal-title":"J. Clin. Oncol."},{"key":"55765_CR27","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1245\/s10434-013-3002-x","volume":"20","author":"SA Khan","year":"2013","unstructured":"Khan, S. A. Surgery for the intact primary and stage IV breast cancer\u2026lacking \u201crobust evidence\u201d. Ann Surg Oncol 20, 2803\u20132805 (2013).","journal-title":"Ann Surg Oncol"},{"key":"55765_CR28","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1245\/s10434-007-9547-9","volume":"14","author":"SA Khan","year":"2007","unstructured":"Khan, S. A. Primary Tumor Resection in Stage IV Breast Cancer: Consistent Benefit, or Consistent Bias? Annals of Surgical Oncology 14, 3285\u20133287 (2007).","journal-title":"Annals of Surgical Oncology"},{"key":"55765_CR29","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1200\/JCO.2016.34.15_suppl.1006","volume":"34","author":"TA King","year":"2016","unstructured":"King, T. A. et al. A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013). Journal of Clinical Oncology 34, 1006\u20131006 (2016).","journal-title":"Journal of Clinical Oncology"},{"key":"55765_CR30","unstructured":"Soran, A. et al. Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01. Annals of Surgical Oncology (2018)."},{"key":"55765_CR31","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/S1470-2045(15)00135-7","volume":"16","author":"R Badwe","year":"2015","unstructured":"Badwe, R. et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. The Lancet Oncology 16, 1380\u20131388 (2015).","journal-title":"The Lancet Oncology"},{"key":"55765_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/annonc\/mdx447","volume":"28","author":"F Cardoso","year":"2017","unstructured":"Cardoso, F. et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol 28, 16\u201333 (2017).","journal-title":"Ann Oncol"},{"key":"55765_CR33","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/0008-5472.CAN-16-1536","volume":"77","author":"S Tohme","year":"2017","unstructured":"Tohme, S., Simmons, R. L. & Tsung, A. Surgery for Cancer: A Trigger for Metastases. Cancer Res 77, 1548\u20131552 (2017).","journal-title":"Cancer Res"},{"key":"55765_CR34","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/annonc\/mdn386","volume":"19","author":"R Demicheli","year":"2008","unstructured":"Demicheli, R., Retsky, M. W., Hrushesky, W. J. M., Baum, M. & Gukas, I. D. The effects of surgery on tumor growth: a century of investigations. Ann. Oncol. 19, 1821\u20131828 (2008).","journal-title":"Ann. Oncol."},{"key":"55765_CR35","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1158\/0008-5472.CAN-03-2646","volume":"64","author":"EA Danna","year":"2004","unstructured":"Danna, E. A. et al. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 64, 2205\u20132211 (2004).","journal-title":"Cancer Res"},{"key":"55765_CR36","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm0806-875","volume":"12","author":"L Norton","year":"2006","unstructured":"Norton, L. & Massague, J. Is cancer a disease of self-seeding? Nat Med 12, 875\u2013878 (2006).","journal-title":"Nat Med"},{"key":"55765_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.canlet.2012.05.021","volume":"324","author":"P Chiarella","year":"2012","unstructured":"Chiarella, P., Bruzzo, J., Meiss, R. P. & Ruggiero, R. A. Concomitant tumor resistance. Cancer Lett. 324, 133\u2013141 (2012).","journal-title":"Cancer Lett."},{"key":"55765_CR38","doi-asserted-by":"crossref","unstructured":"Khan, S. A., Stewart, A. K. & Morrow, M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery, 132, 620\u2013626; discussion 626\u2013627 (2002).","DOI":"10.1067\/msy.2002.127544"},{"key":"55765_CR39","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1200\/JCO.2005.04.2226","volume":"24","author":"E Rapiti","year":"2006","unstructured":"Rapiti, E. et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J. Clin. Oncol. 24, 2743\u20132749 (2006).","journal-title":"J. Clin. Oncol."},{"key":"55765_CR40","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1245\/s10434-007-9438-0","volume":"14","author":"J Gnerlich","year":"2007","unstructured":"Gnerlich, J. et al. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988\u20132003 SEER data. Annals of Surgical Oncology 14, 2187\u20132194 (2007).","journal-title":"Annals of Surgical Oncology"},{"key":"55765_CR41","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.ejso.2009.03.012","volume":"35","author":"J Ruiterkamp","year":"2009","unstructured":"Ruiterkamp, J. et al. Surgical resection of the primary tumour is associated with improved survival in patients with distant metastatic breast cancer at diagnosis. Eur J Surg Oncol 35, 1146\u20131151 (2009).","journal-title":"Eur J Surg Oncol"},{"key":"55765_CR42","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/SLA.0b013e3181656d32","volume":"247","author":"DK Blanchard","year":"2008","unstructured":"Blanchard, D. K., Shetty, P. B., Hilsenbeck, S. G. & Elledge, R. M. Association of surgery with improved survival in stage IV breast cancer patients. Annals of Surgery 247, 732\u2013738 (2008).","journal-title":"Annals of Surgery"},{"key":"55765_CR43","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10549-017-4309-2","volume":"165","author":"T-K Yoo","year":"2017","unstructured":"Yoo, T.-K. et al. Identifying long-term survivors among metastatic breast cancer patients undergoing primary tumor surgery. Breast Cancer Research and Treatment 165, 109\u2013118 (2017).","journal-title":"Breast Cancer Research and Treatment"},{"key":"55765_CR44","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1002\/cncr.23870","volume":"113","author":"HW Hazard","year":"2008","unstructured":"Hazard, H. W. et al. Surgical resection of the primary tumor, chest wall control, and survival in women with metastatic breast cancer. Cancer 113, 2011\u20132019 (2008).","journal-title":"Cancer"},{"key":"55765_CR45","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jss.2008.12.030","volume":"161","author":"AM Leung","year":"2010","unstructured":"Leung, A. M., Vu, H. N., Nguyen, K. A., Thacker, L. R. & Bear, H. D. Effects of surgical excision on survival of patients with stage IV breast cancer. J Surg Res 161, 83\u201388 (2010).","journal-title":"J Surg Res"},{"key":"55765_CR46","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10549-011-1648-2","volume":"129","author":"L Dominici","year":"2011","unstructured":"Dominici, L. et al. Surgery of the primary tumor does not improve survival in stage IV breast cancer. Breast Cancer Res Treat 129, 459\u2013465 (2011).","journal-title":"Breast Cancer Res Treat"},{"key":"55765_CR47","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2017.35.15_suppl.557","volume":"35","author":"F Fitzal","year":"2017","unstructured":"Fitzal, F. et al. Primary operation in synchroneous metastasized invasive breast cancer patients: First oncologic outcomes of the prospective randomized phase III ABCSG 28 POSYTIVE trial. Journal of Clinical Oncology 35, 557\u2013557 (2017).","journal-title":"Journal of Clinical Oncology"},{"key":"55765_CR48","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/978-3-319-70197-4_6","volume":"173","author":"SA Khan","year":"2018","unstructured":"Khan, S. A. & DesJardin, E. S. M. Readdressing the Role of Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer. Cancer Treat. Res. 173, 73\u201388 (2018).","journal-title":"Cancer Treat. Res."},{"key":"55765_CR49","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1245\/s10434-008-9830-4","volume":"15","author":"R Rao","year":"2008","unstructured":"Rao, R. et al. Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol 15, 1696\u20131702 (2008).","journal-title":"Ann Surg Oncol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55765-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55765-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55765-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T18:02:07Z","timestamp":1671300127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55765-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,27]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["55765"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-55765-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,27]]},"assertion":[{"value":"17 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. L\u00f3pez-Tarruella has consultancy\/advisory role for AstraZeneca, Novartis, Roche, Pfizer, Celgene, Pierre-Fabre, Eisai and Lilly. Dr. Garc\u00eda-S\u00e1enz has received consultancy\/speaker fees from Novartis, Celgene, Eli Lilly, EISAI and Roche. Travel support from Novartis, Roche as well as Pfizer and his institution\u2019s research funding from AstraZeneca. Dr. Jara has received speaker fees from Roche, Pfizer, Eisai, Novartis and Kyowa as well as travel support from Roche and Pfizer. Dr. Mart\u00ednez has received consultancy\/speaker fees from Leo Pharma, AstraZeneca, Pfizer, and Tesaro as well as travel support from Roche, Rovi and Boehringer Ingelheim. Dr. Mart\u00edn has a consultant or advisory role with AstraZeneca, Novartis, Roche-Genentech, Pfizer, Glaxo, PharmaMar, Taiho Oncology and Lilly; he has received honoraria from Pfizer and Lilly; he has received research funding from Novartis and Roche. Dr. Guerrero has received travel support from Pfizer. Dr. Ant\u00f3n has consultant\/advisory role for Roche and Bayern. Dr. Carrasco has received travel support from Roche and her institution has received funding from Roche, Novartis, Pfizer, BMS, Celgene, AstraZeneca and MSD. Dr. Llombart has received honoraria from Roche, Lilly, Pfizer and Novartis; he has a consultant\/advisory role for Roche; he has received funding from Roche, Eisai, AstraZeneca, Lilly and Pfizer and has stock ownership from MedSIR. The rest of the authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20081"}}